<DOC>
	<DOC>NCT01723891</DOC>
	<brief_summary>Study to compare safety and pharmacokinetic properties of surfolase capsule and HT-002-01 after oral administration for one day in healthy male volunteer.</brief_summary>
	<brief_title>Study To Compare Safety and Pharmacokinetic Properties of Surfolase Capsule and HT-002-01 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>1. healthy male subjects between the age of 20 and 55 years with body mass index between 18.5 and 25 2. Volunteers without apriority of chronic disease 3. Volunteers must be in good health as determined by the investigator based on a detailed medical history, full physical examination, electrocardiogram, laboratory tests and urinalysis 4. Volunteers who comply with the protocol, understand and sign an informed consent 1. Sensitive response to acebrophylline and xanthine 2. Galactose intolerance, Lapp lactase deficiency and GlucoseGalactose Malabsorption 3. Known history of renal, hepatic, respiratory, neurologic, endocrine, cardiac vascular and hematopoietic disease, especially gallstone 4. Known history of gastrointestinal disease which affects the absorption of medicine. 5. Excluded by screening tests 6. Upper limit of AST, ALT&gt;1.25 times Upper limit of total bilirubin&gt;1.5 times 7. Estimated GFR&lt;80mL/min/1.73m2) 8. systolic blood pressure &lt; 90 or &gt; 150, diastolic blood pressure &lt;50 or &gt;100 9. Known history of drug abuse 10. caffeine&gt;5cups/day, alcohol&gt;210g/week, 10 more cigarettes/day 11. Use of any prescription drug within 14days or overthecounter (OTC) medication within 7 days prior to dosing 12. Participation in any clinical investigation within 60 days prior to study start 13. Donation of blood within 60 days, donation of component blood within 30days 14. Judged by the investigators to be undesirable as subjects</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>